Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCN3718 | Chamaechromone |
| 1. Chamaechromone has anti-HBV and insecticidal activity. 2. Chamaechromone can undergo extensive phase I and phase II metabolism in rat. 3. The hydroxylation of Chamaechromone is inhibited by α-naphthoflavone, and predominantly catalyzed by recombinant human cytochrome P450 1A2. | |
| BCN3720 | Gama-Tocotrienol |
| 1. Gamma-Tocotrienol has antioxidant activity, it as a hypocholesterolemic and antioxidant agent in rats fed atherogenic diets. 2. Gamma-Tocotrienol can induce the apoptosis on human gastric cancer SGC-7901 cells via mitochondria-dependent apoptosis pathway, it may as a potential, new chemopreventive agent for human gastric cancer. 3. Gamma-Tocotrienol is a novel blocker of the STAT3 activation pathway, with a potential role in future therapies for HCC and other cancers. | |
| BCN3721 | Ginsenoside Rk2 |
| Ginsenoside Rk1 has anti-tumor, and anti-platelet aggregation activities. Ginsenoside Rk1 can strongly inhibit permeability induced by VEGF, advance glycation end-product, thrombin, or histamine in human retinal endothelial cells, it reduces the vessel leakiness of retina in a diabetic mouse model; this anti-permeability activity of Rk1 is correlated with enhanced stability and positioning of tight junction proteins at the boundary between cells; Rk1 induces phosphorylation of myosin light chain and cortactin, which are critical regulators for the formation of the cortical actin ring structure and endothelial barrier. | |
| BCN3724 | Alpha-Tocotrienol |
| 1. Alpha-Tocotrienol can exert anti-apoptotic neuroprotective action independently of its antioxidant property. 2. Alpha-Tocotrienol inhibits osteoclastic bone resorption by suppressing RANKL expression and signaling and bone resorbing activity. 3. Alpha-Tocotrienol supplementation counteracts the lipid peroxidation but not the barrier perturbation in the stratum corneum (SC) induced by 10% benzoyl peroxide (BPO). | |
| BCN3725 | Beta-Tocotrienol |
| 1. Beta-Tocotrienol to serve as a new anticancer agent for treating human lung and brain cancers. 2. Beta-Tocotrienol inhibits the growth of both A549 (GI50=1.38±0.334μM) and U87MG (GI50=2.53±0.604μM) cells at rather low concentrations. | |
| BCN3727 | Notoginsenoside T5 |
| 1. Total panax notoginsenosides (TPNS) are the main active ingredients in San-Chi, the root of(Burk) F.H. Chen, which belongs to the Araliaceae family and has been used in traditional Chinese medicine to treat atherosclerosis;TPNS can prevent atherosclerosis by lowering serum lipid levels and regulating vascular CD40 and MMP-9 expression, TPNS may have implications for clinical treatment of atherosclerosis vascular disease. | |
| BCN3729 | Cis-N-Feruloyltyramine |
| 1. Cis-N-Feruloyltyramine shows cytotoxicity against the P-388 cancer cell line. 2. N-cis-Feruloyltyramine and N-trans-Feruloyltyramine are the inhibitors of in vitro prostaglandin (PG) synthesis. | |
| BCN3731 | Dihydrobonducellin |
| 1. Dihydrobonducellin has immunopharmacological activity, it significantly inhibits the production of IL-2 and IFN-gamma in activated PBMC in a concentration-dependent manner. | |
